Product Program year 2025 Source: CMS Open Payments

Hemlibra

Biological Hematology

NDC 50242-920-01

Open in the dashboard

General payments

$7,400,575

4,852 payments

Research payments

$12,739,942

953 payments

Through program year 2025, $7,400,575 in general payments and $12,739,942 in research payments were reported against Hemlibra (Hematology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $347,380 705
2025 Research $3,532,950 108
2024 General $265,528 572
2024 Research $3,919,541 161
2023 General $398,441 631
2023 Research $1,466,587 114
2022 General $546,774 837
2022 Research $1,542,092 119
2021 General $528,920 757
2021 Research $812,291 117
2020 General $257,972 183
2020 Research $940,683 219
2019 General $5,055,559 1,167
2019 Research $525,798 115

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech, Inc. $4,145,248 401 payments
  2. Genentech USA, Inc. $2,818,258 4,228 payments
  3. F. Hoffmann-La Roche AG $364,615 198 payments
  4. Roche Products Limited $44,996 14 payments
  5. Hoffmann-La Roche Limited $27,457 11 payments
Top recipients General payments · program year 2025
  1. Guy Young Pediatric Hematology-Oncology · Bozeman, MT $17,204 5% · 14 payments
  2. Robert Sidonio Pediatric Hematology-Oncology · Atlanta, GA $14,275 4% · 11 payments
  3. Lynn Malec Pediatric Hematology-Oncology · Milwaukee, WI $14,235 4% · 15 payments
  4. Anjlee Mahajan Hematology & Oncology · Sacramento, CA $12,823 4% · 4 payments
  5. Rebecca Kruse-Jarres Hematology & Oncology · Seattle, WA $11,769 3% · 11 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pediatric Hematology-Oncology Pediatrics $214,377 63% · 99 practitioners
  2. Hematology & Oncology Internal Medicine $62,901 18% · 35 practitioners
  3. Nurse Practitioner $17,617 5% · 17 practitioners
  4. Hematology Internal Medicine $15,062 4% · 11 practitioners
  5. Nurse Practitioner, Pediatrics Nurse Practitioner $8,765 3% · 18 practitioners

The top 5 of 29 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $34,807 10% · 33 recipients
  2. North Carolina $27,987 8% · 8 recipients
  3. New York $23,051 7% · 15 recipients
  4. Georgia $20,948 6% · 6 recipients
  5. Michigan $19,003 5% · 12 recipients

The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to HEMLIBRA
Billing code Providers Services Paid by Medicare
Injection, emicizumab-kxwh, 0.5 mg J7170 7 1,367,382 $54,620,684

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

4,852 general · 953 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record